Celldex Therapeutics Inc., of Needham, Mass., presented Phase II data showing rindopepimut (CDX-110) resulted in final overall survival of 24.6 months from diagnosis of EGFRvIII-positive glioblastoma, compared to 15.2 months for a historic control.